"Our experience with Fusion has been a great one. Management, administration and the technical staff all provided excellent service as we generated and optimized a range of humanized antibody variants. More specifically, we were very impressed with Fusions technical knowledge and breadth of expertise. We also greatly appreciated the sense of urgency applied to our program in terms of proposal generation and approval, completion of promised work, direct communication of draft results and return of reports."

Kevin Peters, SVP and CSO, Aerpio Therapeutic

"I wanted to recommend the company Fusion Antibodies. As a client, we had an extremely successful first contract some years ago for the production and engineering of a novel antibody. The team is well experienced, available for all questions, and the quality is high. I do recommend working with them for profiting of their expertise on MAbs projects."

Orfeu Flores, CEO, Stab Vida

"We have worked with Fusion for about 5 years now and we have developed antibodies and kits for research and soon-to be IVD use throughout the world. The recent granting of our patent will lead to further work together for a number of years. Fusion have provided us with tremendous support from all sides including highly specialist work in the genesis of our ?Sentinel Pathway for Cancer? kits including the development of a totally unique hybrid antibody with significant therapeutic as well as diagnostic value. We look forward to working with all the folks at Fusion for many years to come. We cherish and deeply value our relationship."

Tam Herd, CEO, C-Term Diagnostics

"I am very pleased with Fusion Antibodies humanization services to both our Rat Ab targets. The turnaround was fast and efficient and I would use their services again in the future"

Dr Taku Nagai, Department of Immunology, Kagoshima University, Japan

"Fusion Antibodies have been collaborating with BizCom Japan, Inc. for several years and have established great relationships between Japanese clients. They jointly delivered humanize antibodies and antibody expression vectors to Japanese customers successfully."

Dr Hiroyasu Nakatani, Managing Director, BizCom Japan, Inc.

"The humanization process has fulfilled all of our expectations. The humanization project progressed according to plan and the new antibodies showed excellent binding affinities and were of a high quality."

Dr Andreas Hald, Finsen Laboratory

"I would like to recommend Fusion Antibodies to Japanese Pharmaceuticals and biotech companies who are developing new therapeutic monoclonal antibodies. NBHL is very pleased with the state of the art Fusion Antibodies’ technologies including humanization and design of monoclonal antibodies for therapeutic purposes. Fusion Antibodies is an indispensable partner for our GPCR mAb platform, MoGRAA® discovery engine, to advance toward clinical development.”

Dr Kiyoshi Takayama Ph.D. Founder and President of NB Health Laboratory Co., Ltd.

Fusion Antibodies